CEO Briefing: AI Compliance and Verification Services: First Movers in an Empty Market
First mover opportunity for Türkiye in the three-layer AI compliance stack.
The Signal
Artificial intelligence has become "an infrastructure that needs to be controlled" rather than "a tool used" in biotechnology. The FDA has received over 500 applications involving AI since 2016; FDA and EMA announced joint principles for AI in drug development in early 2026; EMA is preparing Annex-22 for AI in GMP production. This creates a three-layer compliance stack that mandates explainability, traceability, and algorithmic bias control. McKinsey and Deloitte are ahead in this field; There is no one in Türkiye yet. That's where the first mover advantage is in an empty market — but this window isn't permanent.
Why It Matters
In the first quarter of 2026, the biotech AI market reached $2.5 billion; The AI-biology combination is dominating late-stage investment rounds (Xaira $1.1 billion, Generate Biomedicines $425 million IPO, Isomorphic Labs $600 million). Every AI-enabled drug program requires validation, explainability documentation, and bias checking for regulatory acceptance. Türkiye's more than 100 technoparks are a natural platform for low-cost and EU-oriented professional service.
Three layers come into effect simultaneously. EMA Annex-22 (AI in GMP) + EU AI Act (high-risk systems) + GDPR (health/genetic data). EMA Annex-22 is expected to be finalized in 2026; High-risk liabilities in the EU AI Law come into effect in August 2026. 2026 is the preparation window.
For existing CRO and consulting firms (CROTURK, Ascot Science): AI compliance service is a spin-off capability that can be built on the existing regulatory framework — no greenfield startup required. For technoparks: an "AI-Health Verification Center" concept is suitable for public support in partnership with TÜBİTAK. For those targeting EU/US biotech companies: differentiation should be a combination of EU AI Law + TITCK compliance; McKinsey/Deloitte is ahead in the pure brand race.
The Move
Let's be honest: in this market, brand is everything and players like McKinsey and Deloitte are both prominent and reliable. It is not enough for Türkiye to say "cheaper" alone; must demonstrate real expertise in a specific combination of compliance (EU AI Law + TITCK). Second, the regulatory calendar is volatile — early investment could remain idle if Annex-22 slips. Third, this opportunity is not production, but service; Scaling depends on human capital, and the brain drain is straining precisely this talent pool. Yet the gap is real and the first mover advantage is tangible.
* AI compliance service capacity assessment with CROTURK, Ascot Science and technopark consultancy companies. 2. Preliminary meeting with TÜBİTAK for the "AI-Health Verification Center" concept. 3. 1 pilot AI compliance consultancy project with a local biotechnology company or technopark initiative. 4. Document the combined methodology of EU AI Law + TITCK compliance. 5. First reference sale for Türkiye-based AI compliance service from EU/US to biotechnology companies.
Read the Full Analysis
For the full original analysis, read the Ghost version here: https://www.mesutaydin.link/ceo-brifingi-04-ai-uyum-ve-dogrulama-hizmetleri-bos-bir-pazarin-ilk-hamlecisi/
This article is for strategic information only. It is not legal, investment, or tax advice.